Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients

Bibliography

• World Health Organization (WHO), WHO position paper on the use of hepatitis B vaccines. Wkly Epidem Rec 2004:255-63
   PubMedGoogle Scholar
• Centers for Disease Control (CDC). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States recommendations of the Advisory Committee on Immunization Practices (ACIP) part II: immunization of adults. MMWR 2006;55(RR16):1-25
   PubMedGoogle Scholar
• Pérez-Garcia R, Pérez-Garcia A, Verbeelen D, et al. AM3 (Inmunoferón®) as an adjuvant to hepatitis B vaccination in hemodialysis patients. Kidney Int 2002;61:1845-52
   PubMed Web of Science ®Google Scholar
• Heathcote EJ. Treatment of hepatitis B: the next five years. Clin Med 2007;7(5):472-7
   PubMed Web of Science ®Google Scholar
• Miller ER, Alter MJ, Tokars JI. Protective effect of vaccine in chronic hemodialysis patients. Am J Kidney Dis 1999;33:356-60
   PubMed Web of Science ®Google Scholar
• Peces R, Laurés AS. Persistence of immunologic memory in long-term hemodialysis patients and healthcare workers given hepatitis B vaccine: role of a booster dose on antibody response. Nephron 2001;89(2):172-6
   PubMed Web of Science ®Google Scholar
• McNulty CA, Bowen JK, Williams AJ. Hepatitis B vaccination in predialysis chronic renal failure patients a comparison of two vaccination schedules. Vaccine 2005;23:4142-7
   PubMed Web of Science ®Google Scholar
• Bruguera M, Rodicio JL, Alcazar JM, et al. Effects of different dose levels and vaccination schedules on immune response to a recombinant DNA hepatitis B vaccine in haemodialysis patients. Vaccine 1990;8(Suppl 1):S47-9
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Hepatitis: control measures for hepatitis B in dialysis centers. US Department of Healthy, Education and Welfare, Public Health Services, CDC, 1977. HEW publication no. (CDC) 78-8358 (Viral Hepatitis Investigations and Control Series)
   Google Scholar
• Alter MJ, Favero MS, Peterson NJ, et al. National surveillance of dialysis-associated hepatitis and other diseases: 1976 and 1980. Dial Transplant 1983;12:860-5
   Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Recommendations of the Immunization Practices Advisory Committee (ACIP): inactivated hepatitis B virus vaccine. MMWR 1982;31:317-22, 327-8
   PubMedGoogle Scholar
• Poland GA. Evaluating existing recommendations for hepatitis A and B vaccination. Am J Med 2005;118(Suppl 10A):16S-20S
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1991;40(RR-13):1-19
   PubMedGoogle Scholar
• Chau K, Cheng Y, Tsang D, et al. Efficacy and side effects of intradermal hepatitis B vaccination in CAPD patients: a comparison with the intramuscular vaccination. Am J Kidney Dis 2004;43:910-7
   PubMed Web of Science ®Google Scholar
• Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant 2004;4(Suppl 10):160-3
   Google Scholar
• Johnson D, Fleming S. The use of vaccines in renal failure. Clin Pharmacokinet 1992;22(6):434-46
   PubMed Web of Science ®Google Scholar
• Sezer S, Ozdemir FN, Güz G, et al. Factors influencing response to hepatitis B virus vaccination in hemodialysis patients. Transplant Proc 2000;32:607
   PubMed Web of Science ®Google Scholar
• Navarro JF, Teruel JL, Mateos ML, et al. Antibody level after hepatitis B vaccination in haemodialysis patients: influence of hepatitis C virus infection. Am J Nephrol 1996;16:95
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Guidelines for vaccinating kidney dialysis patients and patients with chronic kidney disease. Summarized from the Recommendations of the Advisory Committee on Immunization Practices (ACIP). June 2006
   Google Scholar
• Stevens CE, Szmuness W, Goodman AI, et al. Hepatitis B vaccine: immune responses in hemodialysis patients. Lancet 1980;2:1211-3
   PubMed Web of Science ®Google Scholar
• Seaworth B, Drucker J, Starline J, et al. Hepatitis B vaccines in patients with chronic renal failure before dialysis. J Infect Dis 1988;157:332-7
   PubMed Web of Science ®Google Scholar
• Safary A, André F. Over a decade of experience with a yeast recombinant hepatitis B vaccine. Vaccine 2000;18:56-67
   Google Scholar
• Verkade MA, van de Wetering J, Klepper M, et al. Peripheral blood dendritic cells and GM-CSF as an adjuvant for hepatitis B vaccination in hemodialysis patients. Kidney Int 2004;66(2):614-21
   PubMed Web of Science ®Google Scholar
• Cruciani M, Mengoli C, Serpelloni G, et al. Granulocyte macrophage colony-stimulating factor as an adjuvant for hepatitis B vaccination: a meta-analysis. Vaccine 2007;25(4):709-18
   PubMed Web of Science ®Google Scholar
• Van Geelen JA, Schalm SW, De Visser EM, Heijtink RA. Immune response to hepatitis B vaccine in hemodialysis patients. Nephron 1987;45:216-8
   PubMedGoogle Scholar
• Bruguera M, Cremades M, Mayor A, et al. Immunogenicity of a recombinant hepatitis B vaccine in haemodialysis patients. Postgrad Med J 1987;63(Suppl 2):155-8
   PubMed Web of Science ®Google Scholar
• Bruguera M, Rodicio JL, Alcazar JM, et al. Effects of different dose levels and vaccination schedules on immune response to a recombinant DNA hepatitis B vaccine in haemodialysis patients. Vaccine 1990;8(Suppl 1):S47-9
   PubMed Web of Science ®Google Scholar
• Waite NM, Thomson LG, Goldstein MB. Successful vaccination with intradermal hepatitis B vaccine in hemodialysis patients previously nonresponsive to intramuscular hepatitis B vaccine. J Am Soc Nephrol 1995;5:1930-4
   PubMed Web of Science ®Google Scholar
• Chang PC, Schrander-Van Der Meer AM, Van Dorp WT, Van Leer E. Intracutaneous versus intramuscular hepatitis B vaccination in primary non-responding haemodialysis patients. Nephrol Dial Transplant 1996;11:191-3
   PubMed Web of Science ®Google Scholar
• Pashine A, Valiante NM, Ulmer JB. Targeting the innate immune response with improved vaccine adjuvants. Nat Med 2005;11(4 Suppl):S63-8
   PubMed Web of Science ®Google Scholar
• Lindblad EB. Aluminium adjuvants-in retrospect and prospect. Vaccine 2004;22:3658-68
   PubMed Web of Science ®Google Scholar
• Ulrich JT, Myers KR. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharm Biotech 1995;6:495:524
   Google Scholar
• Evans JT, Cluff CW, Johnson DA, et al. Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529. Expert Rev Vaccines 2003;2(2):219-29
   PubMedGoogle Scholar
• Thoelen S, Van Damme P, Mathei C, et al. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 1998;16(7):708-14
   PubMed Web of Science ®Google Scholar
• Thoelen S, De Clercq N, Tornieporth N. A prophylactic hepatitis B vaccine with a novel adjuvant system. Vaccine 2001;19:2400-3
   PubMed Web of Science ®Google Scholar
• Ambrosch F, Wiedermann G, Kundi M, et al. A hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 2000;8(20):2095-101
   Web of Science ®Google Scholar
• Boland G, Beran J, Lievens M, et al. Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04. Vaccine 2004;23(3):316-20
   PubMed Web of Science ®Google Scholar
• Levie K, Gjorup I, Skinhøj P, Stoffel M. A 2-dose regimen of a recombinant hepatitis B vaccine with the immune stimulant AS04 compared with the standard 3-dose regimen of Engerix-B in healthy young adults. Scan J Infect Dis 2002;34:610-4
   PubMed Web of Science ®Google Scholar
• Desombere I, Van der Wielen M, Van Damme P, et al. Immune response of HLA DQ2 positive subjects, vaccinated with HBsAg/AS04, a hepatitis B vaccine with a novel adjuvant. Vaccine 2002;20:2597-602
   PubMed Web of Science ®Google Scholar
• Kong NCT, Beran J, Kee SA, et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int 2005;68(5):2298-303
   PubMed Web of Science ®Google Scholar
• Kong NCT, Beran J, Kee SA, et al. Persistence of anti-HBs antibody seroprotection rates and safety of an adjuvanted hepatitis B vaccine in pre-haemodialysis and haemodialysis patients. ISVHDL, Paris, France (Poster)
   Google Scholar
• Kundi M. New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev Vaccines 2007;6(2):133-40
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Martin P. A new single-dose hepatitis B vaccine versus a conventional vaccine in patients with end-stage renal disease. Nat Clin Pract Nephrol 2006;2(7):356-7
   PubMedGoogle Scholar
• Shouval D. Hepatitis B vaccines. J Hepatol 2003;39:S70-6
   PubMed Web of Science ®Google Scholar
• Shapira MY, Zeira E, Adler R, Shouval D. Rapid seroprotection against hepatitis B following the first dose of pre-S1/S vaccine. J Hepatol 2001;34:123-7
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364:1757-65
   PubMed Web of Science ®Google Scholar
• Alonso PL, Sacarlal J, Aponte JJ, et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 2004;364:1411-20
   PubMed Web of Science ®Google Scholar
• Stanberry LR, Sprunance SL, Cunningham AL, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002;347(21):1652-61
   PubMed Web of Science ®Google Scholar
• Bartz H, Mendoza Y, Gebker M, et al. Poly-guanosine strings improve cellular uptake and stimulatory activity of phosphodiester CpG oligonucleotides in human leukocytes. Vaccine 2004;23(2):148-55
   PubMed Web of Science ®Google Scholar
• Poland GA. Evaluating existing recommendations for hepatitis A and B vaccination. Am J Med 2005;118(Suppl 10A):16S-20S
   PubMed Web of Science ®Google Scholar
• Charest AF, McDougall J, Goldstein MB. A randomized comparison of intradermal and intramuscular vaccination against hepatitis B virus in incident chronic hemodialysis patients. Am J Kidney Dis 2000;36:976-82
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Andrulli S, Bacchini G, Corti M, Locatelli F. Intradermal versus intramuscular hepatitis B re-vaccination in non-responsive chronic dialysis patients: a prospective randomized study with cost-effectiveness evaluation. Nephrol Dial Transplant 1997;12:1204-11
   PubMed Web of Science ®Google Scholar
• Navarro JF, Teruel JL, Mateos ML, Marcen R, Ortuno J. Antibody level after hepatitis B vaccination in hemodialysis patients: influence of hepatitis C virus infection. Am J Nephrol 1996;16:95-7
   PubMed Web of Science ®Google Scholar
• Seaworth B, Drucker J, Starling J, Drucker R, Stevens C, Hamilton J. Hepatitis B vaccines in patients with chronic renal failure before dialysis. J Infect Dis 1988;157:332-7
   PubMed Web of Science ®Google Scholar
• Marangi AL, Giordano R, Montanaro A, et al. Hepatitis B virus infection in chronic uremia: long-term follow-up of a two-step integrated protocol of vaccination. Am J Kidney Dis 1994;23:537-42
   PubMed Web of Science ®Google Scholar